At the 8th China International Import Expo, Boehringer Ingelheim held the launch ceremony of its drug Sutentan (zalotinib tablets) in China. This is the world's first and only orally administered HER2 tyrosine kinase inhibitor (TKI) approved for non-

Lung cancer is one of the most prevalent and deadly malignancies in China. According to statistics, there were over 1.06 million new cases of lung cancer in China in 2022, with non-small cell lung cancer accounting for approximately 80% to 85%. Among

Previously, there had been no breakthrough in TKI targeted therapy in the treatment of HER2 lung cancer, but the approval of drug for St. Hypoteny has brought new treatment options and hope for HER2 lung cancer patients. Tu Haiyan, the director of Pu

The accelerated approval of Sintai Drug in China is benefited from the priority review and approval policy. Last year, Sintai Drug successively obtained the qualifications of breakthrough therapy recognition and priority review awarded by the Nationa

Chen Wenhan, the general manager of Boehringer Ingelheim's human pharmaceutical business in the greater China region, said that thanks to the high support and recognition of China's drug regulatory department for innovative products, the launch of St

Oncology is one of the key business areas for Boehringer Ingelheim. In recent years, the company has actively promoted the expansion and improvement of its oncology research and development pipeline, covering cancer cell targeting, immunotherapy, and